Skip to main content
Equibles
ONC logo

ONC

BeOne Medicines Ltd.
$298.70 -4.13 (-1.36%) At close · Jul 10
Market Cap
$431.70B
Shares
1,445,262,342

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$298.70 Open$303.03 Day$295.39–304.77 52W$249.00–385.22 Avg vol 30d294K Short int792K · 0.1% float · 2.7d Short vol66% Last earningsFeb 26, 2026 DataJan 2020–Jul 2026 Filing10-Q · May 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 6, 2026
AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Equibles Rating blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Moderate
      Market backdrop VIX 15 · calm Equity put/call 0.55
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −5%
      below
      Price vs 50-day avg +3%
      above
      RSI (14) 58
      neutral
      MACD trend Positive
      52-week position 36%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +13%
      trailing
      6-month return −12%
      trailing
      YTD return −2%
      this year
      Relative strength −21%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $290 › 200d $315 — 200d above 50d
      Institutional flow Distributing
      8 of 282 funds reported for Jun 30 · net -2.6K sh shares · +1 new
      Insider flow Distributing
      Net -$7.6M over 90 days · 100% sells
      Short interest Falling
      0.05% of float · ▼ -12.3% MoM · 2.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      282 holders — near 3-yr high, broad support
      Squeeze score 38
      low risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +22179%
      Y/Y
      Gross margin 1961%
      contracting
      EPS growth +140%
      Y/Y
      Free cash flow $941.7M
      Valuation P/E 878.5
      rich
      Balance sheet $3.7B
      net cash
      Quant / Vol
      risk profile
      Moderate
      Volatility 41%
      annualized · 1-yr
      Max drawdown −31%
      past year
      ATR 3.0%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record
      Latest guidance · from the 8-K filed May 6, 2026
      Total revenue · Full Year 2026 Initiated $6.3B – $6.5B
      prior FY $5.34B midpoint +19.8% Y/Y
      GAAP operating expenses (combined R&D and SG&A) · Full Year 2026 Initiated $4.7B – $4.9B
      GAAP operating income · Full Year 2026 Initiated $750M – $850M
      Non-GAAP operating income · Full Year 2026 Initiated $1.45B – $1.55B

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −5% Bearish
      Price vs 50-day avg
      +3% Bullish
      RSI (14)
      58 Neutral
      MACD trend
      Positive Bullish
      52-week position
      36% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $290 › 200d $315 — 200d above 50d
      Institutional flow Distributing
      8 of 282 funds reported for Jun 30 · net -2.6K sh shares · +1 new
      Insider flow Distributing
      Net -$7.6M over 90 days · 100% sells
      Short interest Falling
      0.05% of float · ▼ -12.3% MoM · 2.7 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      282 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      52-wk low $249 Now $299 · 36% 52-wk high $385
      vs 200-day avg -5% vs 50-day avg +3%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      Amgen in-licensed products global sales 142M first quarter of 2026 —
      BRUKINSA global sales 1.1B first quarter of 2026 —
      BRUKINSA U.S. sales 761M first quarter of 2026 —
      Gross Margin as a percentage of global product sales 89% first quarter of 2026 —
      SG&A expenses as a percentage of product sales 37% first quarter of 2026 —
      Gross Margin ratio - China 66.6% For the year ended December 31, 2025 —
      Key products production quantity 6,268,800 For the year ended December 31, 2025 —
      Key products sales quantity 5,996,100 For the year ended December 31, 2025 —
      Key products stock quantity 2,912,600 As of December 31, 2025 —
      R&D expenses - Other R&D projects $311,557K For the year ended December 31, 2025 —
      R&D expenses - R&D collaboration projects $104,852K For the year ended December 31, 2025 —
      R&D expenses - Subtotal of external R&D expenses $858,720K For the year ended December 31, 2025 —
      R&D expenses - Subtotal of internal R&D expenses $1,287,148K For the year ended December 31, 2025 —
      R&D expenses - Total $2,145,868K For the year ended December 31, 2025 —
      Gross Margin (Adjusted) non-GAAP 87.8% Full Year 2025 —
      Gross Margin (GAAP) 87.3% Full Year 2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      ONC
      BeOne Medicines Ltd.
      this stock
      		$431.70B -1.7% +22179.2% 878.5 0.1%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $123.19B +7.1% +46.2% 28.8 1.9%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $69.63B -13.8% +20.8% 16.2 3.3%
      ARGX
      Argenx SE
      		 $54.85B +4.4% — — 2.3%
      CSLLY
      Csl Ltd
      		 $41.40B -24.0% — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      281
      % held
      2.4%
      Reported
      8 of 282
      Top holder
      BAKER BROS. ADVISORS LP
      Held Float
      View
      Held by Funds
      Fund positions
      115
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      791.6K
      Days to cover
      2.7d
      Change
      -110.8K sh
      View
      Short Volume
      Short vol %
      66%
      As of
      Jul 10, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      18
      Value
      $4.7K
      As of
      Jun 11, 2026
      View
      Off-Exchange
      Off-exchange %
      62.8%
      Week of
      May 4, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$7.6M
      Buyers / Sellers
      0 / 11
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $5.3B
      Net income (FY)
      $286.9M
      EPS diluted
      $0.19
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Jun 30, 2026
      This year
      10
      View
      Proposed Sales
      Value
      $15.0M
      Shares
      49.5K
      Filed
      Jul 10, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jun 8, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      ONC +0.4% +13.3% -11.7% +4.8% -1.7%
      SPY +1.4% +4.1% +9.1% +1.1% +10.7%
      vs SPY -1.0% +9.2% -20.8% +3.7% -12.4%
      Key facts CIK 1651308 CUSIP 07725L102 13F (30d) 29 filings 9 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)